The past decade, since the first human genome was sequenced, has witnessed an explosion of information. Today DNA sequencing is becoming quicker and cheaper enabling the scientist to apply the fruits of their work directly to help patients.
Calbindin immunostaining of wild-type robotic cerebellum sections
The FGU is a leader in the analysis of genomic information and applying it to clinical problems, particularly neurological disorders such as Parkinson’s disease, muscular dystrophy, motor neuron disease, intellectual disability and schizophrenia.
We are working closely with our clinical colleagues and the major charities (Action Duchenne, Parkinson’s UK, Motor Neuron Disease Association, Muscular Dystrophy Campaign and Muscular Dystrophy Association, USA) to deliver better diagnosis and treatment for patients.